Skip to main content
Clinical Trials/NCT03782051
NCT03782051
Completed
Not Applicable

Combined Phacoemulsification and Viscocanalostomy With Ologen Implant Versus Combined Phacoemulsification and Viscocanalostomy

Zagazig University1 site in 1 country81 target enrollmentAugust 1, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Open-angle Glaucoma
Sponsor
Zagazig University
Enrollment
81
Locations
1
Primary Endpoint
the intraocular pressure
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This prospective, interventional, randomized clinical study was done at Alpha Vision Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive either phaco-viscocanalostomy (Phacovisco group) or phaco-viscocanalostomy with Ologen® implant (OloPhacovisco group) . Follow-up period was 2 years. Nd:YAG laser goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.

Our hypothesis is that using Ologen® implant as a spacer in the subscleral reservoir in phaco-viscocanalostomy reduces fibrosis and increase the success rate of this operation

Detailed Description

Background: To study the efficacy of the biodegradable collagen implant Ologen® as an adjuvant in phaco-viscocanalostomy in patients with coexisting cataract and primary open angle glaucoma. Methods: This prospective, interventional, randomized clinical study was done at Alpha Vision Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive either phaco-viscocanalostomy (Phacovisco group) or phaco-viscocanalostomy with Ologen® implant (OloPhacovisco group). Follow-up period was 2 years. Nd:YAG laser goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.

Registry
clinicaltrials.gov
Start Date
August 1, 2013
End Date
January 14, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmed moamen

princibal investigator, lecturer of ophthalmology

Zagazig University

Eligibility Criteria

Inclusion Criteria

  • the presence of significant cataract interfering with vision (visual acuity ≤ 0.5) in the presence POAG.
  • if cataract was associated with uncontrolled glaucoma, (IOP \> 21 mmHg despite maximally tolerated medical therapy)
  • if the IOP was ≤ 21 mmHg with use of at least two antiglaucoma drugs with medication intolerance
  • poor patient compliance
  • patients could not attend medical supervision
  • patients had visual field deterioration.

Exclusion Criteria

  • closed-angle glaucoma
  • other types of open angle glaucoma (OAG), e.g. pigmentary glaucoma, inflammatory glaucoma or neovascular glaucoma,
  • previous ocular trauma or surgery
  • lens subluxation
  • any eye diseases affecting the vision, e.g. anterior uveitis
  • if there was a large perforation of the Descemet's membrane with iris prolapse during surgery (cases with microperforation, which is defined as small perforation with no associated iris prolapse, occurring during surgery were not excluded) intraoperative complications that might affect the IOP, e.g. vitreous loss.

Outcomes

Primary Outcomes

the intraocular pressure

Time Frame: 2 years

measured by mmHg using Goldman applanatin tonometry

Secondary Outcomes

  • surgical complications(2 years)
  • the use and results of Nd:YAG laser goniopuncture(2 years)
  • visual acuity results(2 years)

Study Sites (1)

Loading locations...

Similar Trials